Everything below concerns reversed-phase HPLC. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-06-17. Numbers and descriptions here follow the published literature rather than marketing material.
Most published findings come from rodent models, where the peptide has been examined in wound-healing, gastrointestinal-lesion, tendon, and vascular-injury preparations. A smaller number of early human studies have been reported, chiefly in inflammatory bowel conditions, but the public record is short and has not led to marketing approval in the United States or the European Union. Reviewers therefore classify the compound as investigational, and whether animal results carry over to people remains an open question rather than a settled one.
Outside laboratory supply channels, the peptide is sold as a research chemical, a category that carries no requirement to demonstrate purity, identity, or freedom from contamination. Because it is not an approved medicine, products labeled BPC-157 sit in a regulatory gap in many countries, and actual content may differ from the label. Sports organizations list it among prohibited substances, so its presence in an athlete's sample can produce a doping finding regardless of how the material was obtained.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography, which separates the target peptide from truncated sequences and other synthesis by-products. Mass spectrometry, typically electrospray ionization coupled to liquid chromatography, confirms the expected mass and helps detect modifications. Amino acid analysis can verify composition when residue-level confirmation is needed. Because common impurities differ from the target by only one or two residues, chromatographic resolution often matters more than a single headline purity percentage. Impurity profiles are most informative when compared against a validated reference standard.
Lyophilized material is generally reported as stable for extended periods when kept cold, dry, and protected from light. In solution, the main degradation routes for a peptide of this type are hydrolysis of peptide bonds and aggregation. The sequence contains no cysteine, so disulfide-driven oxidation is not a primary concern, though methionine and tryptophan are also absent. Stability depends on pH, buffer composition, and concentration, with acidic conditions often reported as more favorable than neutral or alkaline ones. Repeated freeze-thaw cycles can promote aggregation, and how fast degradation proceeds at room temperature in specific formulations remains an open question.
| Property | Value | Notes |
|---|---|---|
| Origin | Fragment of a protein found in human gastric juice | Sequence corresponds to a fifteen-residue portion of the parent protein |
| Sequence | GEPPPGKPADDAGLV | Single linear chain, fifteen amino acids |
| Reported molecular weight | About 1419 daltons | Value quoted consistently in supplier and review literature |
| Regulatory status | Not an approved human medicine in the US or EU | Handled and sold as a research chemical |
| Sports status | Listed as prohibited | Falls under non-approved-substance categories in anti-doping codes |
BPC-157 is normally distributed as a lyophilised powder that ranges from white to off-white in appearance. The peptide dissolves readily in water, normal saline, and common aqueous buffers, and it is poorly soluble in nonpolar solvents such as hexane or vegetable oils. Lyophilised vials take up moisture if left open, which changes the mass of powder in the container and complicates any later weighing. Because the material is handled in small quantities, static and adhesion to glass or plastic can also cause noticeable losses during transfer.
The main chemical liabilities of this sequence are peptide-bond hydrolysis and possible aspartate-related reactions, since the peptide contains aspartic acid residues but no cysteine, methionine, or tryptophan. Absence of those three residues removes the most common oxidation and disulfide pathways from consideration. Studies of related peptides indicate that aspartate isomerisation and aspartimide formation occur most readily at Asp-Gly and Asp-Ala positions, and open questions remain about how quickly those reactions proceed under ordinary laboratory conditions. Storage guidance typically emphasises cool, dry, dark conditions to slow hydrolysis.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography, often paired with mass spectrometry using electrospray or MALDI ionisation. Amino acid analysis and peptide mapping by enzymatic digestion provide additional sequence-level confirmation. Purity is commonly reported as an area percentage from a chromatographic trace, and water content can be measured by Karl Fischer titration. Reported masses may differ by tens of daltons between sources because preparations can contain acetate or trifluoroacetate counterions, and such differences are not by themselves evidence of a different peptide.
Laboratory research on this peptide has examined a wide and heterogeneous set of endpoints, including gastric ulcer models, tendon and ligament injury, wound closure, and intestinal inflammation. Most published findings come from rodent studies, and reported effect sizes are often large relative to controls. Because the compound has been tested across many unrelated injury models, the literature is frequently described as unusually broad for a single peptide. A substantial share of this work originates from a small number of research groups, which matters when assessing how widely results have been reproduced.
Evidence in humans is limited. Small clinical studies have examined the peptide in contexts such as ulcerative colitis and wound healing, but participant numbers are small and independent replication is scarce. It is not approved as a medicine by major regulatory agencies and is distributed mainly as a research material or compounded preparation. Long-term human safety data are not established, and questions about absorption through non-injected routes remain open rather than resolved. Claims about its effects are best read against these gaps.
BPC-157 is a synthetic peptide composed of fifteen amino acid residues, with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. Its name derives from body protection compound, a term used for a protein fraction identified in human gastric juice. Researchers in Zagreb first reported the pentadecapeptide in the early 1990s and described it as a stable fragment of that larger protein. The compound is also catalogued as PL 14736 and, in some commercial contexts, as bepecin. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
Most published work on BPC-157 consists of preclinical studies, including rodent models of tissue injury, gastrointestinal lesions, and vascular or tendon damage, together with in vitro cell assays. Reviews frequently note that the mechanisms proposed in these papers remain incompletely characterised and that findings have not been confirmed in large randomised human trials. The compound is widely sold as a research chemical rather than a licensed medicine, and labels commonly carry a statement that it is not for human use. Whether any of the reported animal effects translate to humans is an open question rather than an established result.
Terminology in the literature is not fully standardised. Papers and product listings use BPC-157, BPC 157, and the longer phrase stable gastric pentadecapeptide BPC 157 interchangeably, and synonyms such as bepecin or PL 14736 appear in older or company-linked publications. Purity claims and reported masses can also differ between sources because peptide preparations may include counterions, residual solvents, or bound water. This variability complicates direct comparison of results across studies and makes the exact identity and grade of a given sample worth verifying. Discussions of the compound should therefore specify the source, salt form, and stated purity where those are known.
People who intravenously inject black tar heroin are at higher risk of venous sclerosis than those injecting powder heroin. In this condition, the veins narrow and harden which makes repeated injection there nearly impossible. The presence of 6-monoacetylcodeine found in tar heroin has not been tested in humans but has been shown to be toxic alone and more toxic when mixed with mono- or di- acetyl morphine, potentially making tar more toxic than refined diamorphine. Black tar heroin injectors can be at increased risk of life-threatening bacterial infections, in particular necrotizing soft tissue infection. The practice of "skin-popping" or subcutaneous injection predisposes to necrotizing fasciitis or necrotizing cellulitis from Clostridium perfringens, while deep intramuscular injection predisposes to necrotizing myositis. Tar heroin injection can also be associated with Clostridium botulinum infection, causing botulism. Since the final stage of black tar heroin production would kill any spores (a combination of high temperature and strong acid), contamination is likely due to choice of cutting agent. Almost all cases occur in users who inject intramuscularly or subcutaneously, rather than injecting intravenously. Black tar heroin users can also be at increased risk of bone and joint infections that stem from hematogenous seeding or local extension of the skin and soft tissue infections. Any joint can be infected, though previous studies have shown that the knee and hip are most commonly affected in heroin injectors.
=== Japan === As of February 2026, 94.2% of Japan's crude oil imports came from the Middle East. However, the impacts of the oil supply disruption due to the strait closure were partly mitigated by its large stockpiles. On 16 March, the Government of Japan started releasing 80 million barrels of oil, equivalent to 15 days of domestic demand, from its strategic reserves.
Companies linked to the government control much of the domestic media in Singapore. MediaCorp operates most free-to-air television channels and free-to-air radio stations in Singapore. There are a total of six free-to-air TV channels offered by MediaCorp. StarHub TV and Singtel TV also offer IPTV with channels from all around the world. SPH Media Trust, a body with close links to the government, controls most of the newspaper industry in Singapore. Singapore's media industry has sometimes been criticised for being overly regulated and lacking in freedom by human rights groups such as Freedom House. Self-censorship among journalists is said to be common. In 2023, Singapore was ranked 129 on the Press Freedom Index published by Reporters Without Borders, up from 139 the previous year. The Media Development Authority regulates Singaporean media, claiming to balance the demand for choice and protection against offensive and harmful material. Private ownership of TV satellite dishes is banned. Internet in Singapore is provided by state-owned Singtel, partially state-owned Starhub and M1 Limited as well as some other business internet service providers (ISPs) that offer residential service plans of speeds up to 2 Gbit/s as of spring 2015. Equinix (332 participants) and the Singapore Internet Exchange (70 participants) are Internet exchange points where Internet service providers and Content delivery networks exchange Internet traffic between their networks (autonomous systems) in various locations in Singapore.
Sources: en.wikipedia.org
=== Pharmacokinetics === DOPR crosses the blood–brain barrier in rodents. The drug showed the highest brain/plasma ratio among DOM homologues in rodents, whereas 2,5-dimethoxyamphetamine (2,5-DMA) showed the lowest. This was involved in potency differences between the drugs.
== Other animals == In the long-footed mammals, both the hoofed species (unguligrade) and the clawed forms which walk on the toes (digitigrade), the heel is well above the ground at the apex of the angular joint known as the hock. In plantigrade species, it rests on the ground. In birds, the heel is the backward-pointing joint which is often mistaken as the "knee" (the actual knee of birds is hidden under the plumage).
=== International travel === Zolpidem is among the agents used in the short-term management of insomnia associated with jet lag, typically at doses of 5–10 mg. Its clinical use, similar to that of other hypnotics, is constrained by the potential for adverse effects and dependence, and guidelines generally recommend limiting treatment duration to short periods, usually under one week.
Sources: en.wikipedia.org
It is not approved for human use in the United States or the European Union. Clinical material has been studied in a small number of early trials, mainly for inflammatory bowel conditions, and the compound remains investigational. Regulators treat marketed products as unapproved rather than as authorized drugs.
The peptide was named after a protein fraction found in human gastric juice, and the shorter form was called body protection compound. That phrase was shortened to the abbreviation BPC. The number 157 refers to a laboratory designation used in the original isolation work.
Its sequence corresponds to a segment of a protein present in gastric secretions, but the material supplied for research is made synthetically. No commercial product is purified from human or animal tissue. The synthetic route is used because it gives a defined chain length and a reproducible sequence.
Reversed-phase liquid chromatography with ultraviolet detection gives a purity estimate, while mass spectrometry confirms molecular mass and flags modifications. Amino acid analysis can add compositional confirmation. Results are most meaningful when a validated reference standard is run alongside the sample.